Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

SAGE 01.08.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur SAGE Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Sage and Tractics Announce Partnership to Deliver a Powerhouse Cloud Solution for Heavy Civil Contractors
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.12.2025 - Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.13.2025 - 8-K Current report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2025--Sage Therapeutics, Inc.(NASDAQ: SAGE) today announced that the Company will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2025, at8:15 a.m. PTinSan Francisco, CA.

A live webcast of the presentation can be accessed on the Investor page of Sage’s website atinvestor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

AboutSage TherapeuticsSage Therapeutics(Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered inCambridge, Mass.Find out more atwww.sagerx.comor engage with us onFacebook,LinkedIn,Instagram, andX.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250108981499/en/

InvestorKatie PlanteKatie.Plante@sagerx.com

MediaFrancesca DellelciFrancesca.Dellelci@sagerx.com

Source:Sage Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com